Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Non-Responsive Diabetic Macular Edema and Spironolactone
NCT04853355 · Wake Forest University Health Sciences · PHASE4 · withdrawn · last registry update 2022-08-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of funding” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-01Results posted on the registry: University Hospitals Cleveland Medical Center, Spironolactone + Placebo (NCT02169089)
- 2023-06-13Phase 3 first posted: Bayer, Finerenone (NCT05901831)
- 2023-06-02Results posted on the registry: Massachusetts General Hospital, Eplerenone + Placebo (NCT02740179)
- 2023-05-24Also stopped (withdrawn): Mayo Clinic, Carvedilol + Lisinopril (NCT04190433)
- 2023-05-09Phase 3 first posted: October 6 University, Dapagliflozin Farxiga® + Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone® (NCT05849766)
- 2023-05-03Results posted on the registry: Brigham and Women's Hospital, eplerenone + amiloride (NCT02525796)
- 2023-05-01Results posted on the registry: CMP Development, LLC, Digoxin 250 MCG Oral Tablet + Spironolactone 25 mg/ 5 mL S/F Suspension (NCT03909529)
- 2023-03-31Results posted on the registry: Bayer, Finerenone (Kerendia, BAY94-8862) + Placebo (NCT05013008)
- 2023-03-17Also stopped (withdrawn): University of Cincinnati, Eplerenone 50 Mg Tab + Placebo Oral Tablet (NCT03418649)
- 2023-02-24Results posted on the registry: Vifor Pharma, Inc., Patiromer + Placebos (NCT03888066)
- 2023-02-21Also stopped (withdrawn): University of Michigan, Placebo + Eplerenone 50mg (NCT04746495)
- 2023-02-01Also stopped (withdrawn): University of Texas Southwestern Medical Center, Abiraterone acetate + Placebo (NCT03548246)
- 2023-01-09Phase 3 first posted: Universidade do Porto, Dapagliflozin + Spironolactone + Dapagliflozin (NCT05676684)
- 2022-12-21Results posted on the registry: University of Alabama at Birmingham, Spironolactone + Amiloride (NCT02497300)
- 2022-10-14Phase 3 first posted: Instituto Nacional de Cardiologia Ignacio Chavez, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID + Empagliflozin 10 MG OD (NCT05580510)
- 2022-09-29Results posted on the registry: VA Office of Research and Development, Carvedilol + Spironolactone (NCT02230891)
- 2022-09-19Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sacubitril/valsartan + valsartan (NCT05545059)
- 2022-07-26Results posted on the registry: University of North Carolina, Chapel Hill, Drospirenone-Ethinyl Estradiol Oral Tablet (NCT04278755)
- 2022-07-26Also stopped (terminated): University of North Carolina, Chapel Hill, Drospirenone-Ethinyl Estradiol Oral Tablet (NCT04278755)
- 2022-07-18Phase 3 first posted: Insud Pharma, Drospirenone (NCT05461573)
- 2022-07-13Phase 3 first posted: Bayer, Finerenone (Kerendia, BAY94-8862) (NCT05457283)
- 2022-07-13Results posted on the registry: ReveraGen BioPharma, Inc., Vamorolone + Prednisone (NCT03439670)
- 2022-07-12Phase 3 first posted: Ain Shams University, Fludrocortisone Acetate 0.1 MG (NCT05453214)
- 2022-05-16Results posted on the registry: University Hospitals Cleveland Medical Center, Spironolactone (NCT03597035)
- 2022-05-16Also stopped (terminated): University Hospitals Cleveland Medical Center, Spironolactone (NCT03597035)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision